How to Decide

This page will not tell you what to do. It will give you what you need to decide.

If you are reading this, you or someone you love has been given a diagnosis, and you are trying to understand what options exist. You have probably already found websites that promise recovery, show photographs of smiling patients, and ask you to act quickly.

This page is different. It explains how to evaluate any treatment option you encounter — including the ones coordinated through Human Paths — so that whatever you decide, you decide it with clear information rather than under pressure.

Some people reading this will conclude that exploring treatment abroad makes sense for their situation. Others will conclude it does not. Both are legitimate outcomes, and both are better reached here than later.

Start with the treatment you already have

Do not stop, pause, or delay a treatment your medical team has prescribed in order to pursue another option, without discussing it with them first.

The U.S. Centers for Disease Control and Prevention identifies this specifically as the most serious risk facing cancer patients who seek care abroad. The harm is not only that an unproven treatment may not work — it is that postponing or forgoing an approved therapy can allow a treatable disease to progress.

Many treatments can be explored in parallel with standard care. Some cannot. Only your treating physician knows which situation applies to you, because it depends on your specific diagnosis, your current protocol, and where you are in it.

What this means for you: before you investigate any option, including this one, tell your oncologist that you are looking. You are not asking permission. You are making sure that whatever you decide does not interfere with care that is already working.

What “experimental” actually means

A treatment can be legally available in one country and not approved in another. That difference does not automatically mean it is unsafe, and it does not automatically mean it works.

Regulatory approval in the United States requires evidence from controlled clinical trials showing that a treatment produces a specific benefit for a specific condition. A therapy that has not completed that process may still be under investigation, may have shown promise in early studies, or may simply never have been tested rigorously.

These are very different situations, and they are frequently described using the same word.

There is also a set of terms that sound like approval and are not. Orphan drug designation, fast track, breakthrough therapy status, an active investigational application, or a listing on a public trials registry all mean the same thing: development is underway. None of them means a treatment has been approved, and none of them means it has been shown to work. A registration number is a record that something is being studied, not a result.

What this means for you: when you encounter a treatment described as “available” somewhere, the useful question is not is it legal there but what evidence exists, and what kind.

How to read a claim about evidence

Not all evidence carries the same weight. When you read that a treatment “has been shown” to do something, the specific study design determines how much that statement is worth.

• Case reports and patient stories describe what happened to one person or a few. They cannot tell you whether the treatment caused the outcome, or how often it happens.
• Early-phase studies are usually small and designed to assess safety, not effectiveness. They often have no comparison group.
• Controlled trials compare people who received the treatment against people who did not. This is what allows a claim about effectiveness.
• Systematic reviews examine all available studies together and weigh their quality.

A claim supported by a case report and a claim supported by a controlled trial may sound identical on a website. They are not.

What this means for you: ask which type of study supports any claim you are told. If the answer is vague, treat the claim as unsupported — not as false, but as unproven.

Plausible, active, proven — three different things

When someone tells you a treatment “works,” that sentence can mean three very different things. Separating them is the most useful habit you can build, and it applies to any treatment you look at.

Plausible means there is a credible reason to think it could work. Someone has described how it would act in the body, and it makes biological sense.

Active means something has actually been observed in patients. People received it, and something measurable happened.

Proven means enough good evidence exists, repeated by more than one group, that the treatment improves outcomes that matter — living longer, living better — compared with the alternatives already available.

These are three rungs of a ladder. Most treatments marketed directly to patients sit on the first or the second, described in the language of the third.

A mechanism that makes sense is not the same as a response in a patient. A response in a few patients is not the same as a treatment that does better than what you would otherwise receive.

Being on a lower rung is not the same as having failed. A treatment can be plausible and active and simply not have been tested enough yet. That is a statement about the state of the evidence, not a verdict on the treatment. The two get confused in both directions.

What this means for you: when you read that something “works,” ask which rung it is on. If a provider cannot say which one applies to what they are offering, treat it as the lower one.

Numbers and markers are not results

Two kinds of figure appear constantly in this field, and neither one tells you what it appears to tell you.

A quantity is not a measure of quality. A number describes how much of something was produced, not how well it works. Two products advertised with identical figures can behave completely differently. Unless someone can tell you how the thing was tested for what it is actually supposed to do, the number is packaging.

A change in your body is not the same as a change in your disease. A test can show that something moved — a count went up, a level shifted. That is called a surrogate marker: something measured because it is easy to measure, standing in for the thing you actually care about. It is a signpost, not a destination.

The outcomes that matter to you are the ones you can see or feel: whether the disease shrank on imaging, whether it stayed controlled longer, whether you lived longer, whether you felt better.

A treatment can measurably change your test results without changing any of those. It can also improve how you feel without changing your test results. Neither one proves the other.

What this means for you: when a result is offered as evidence, ask what it predicts. “Your numbers improved” is a reason to keep watching. On its own, it is not a reason to conclude that a treatment is working — or that it is not.

Questions worth asking any provider

These apply to us and to anyone else you are considering.

About the treatment

• What specific evidence supports using this for my diagnosis?
• What kind of studies, and how large?
• What is not yet known?
• What are the risks and side effects?
• What happens if it does not work?

About the process

• Who evaluates whether I am an appropriate candidate?
• What are their credentials, and where are they licensed?
• Can I be told I am not a candidate? How often does that happen?
• Who will be responsible for my care, and who do I contact if something goes wrong?

About money

• Who establishes the cost, and when will I know it?
• What is included and what is not?
• What happens if I need to stop partway through?

About my existing care

• How will this affect the treatment I am already receiving?
• Will my local oncologist receive information about what was done?

If a provider is reluctant to answer any of these directly, that reluctance is itself an answer.

You can ask us every one of these, and we will answer them. Where something is a clinical judgment that belongs to the physician rather than to us, we will say so and tell you who can answer it.

These questions are general, and they work on any provider. If you are looking at a specific therapy there are usually product-level questions as well — the ones for NK cell therapy are in NK Cell Therapy: What the Evidence Shows.

Warning signs

The following are common in this field and should make you more cautious, not less:

• Guaranteed results, or claimed success rates without published studies. No legitimate provider can guarantee an outcome in oncology.
• Testimonials presented as evidence. A recovery story tells you what happened to one person. It cannot tell you what will happen to you.
• Pressure to decide quickly. Limited slots, expiring prices, urgency framing.
• Being told you are a candidate before anyone has reviewed your medical records. No one can assess your case from a phone call or a web form.
• Discouraging you from involving your current medical team. A provider who wants to be your only source of information is protecting something.
• Unclear identity. If you cannot tell whether you are talking to a clinic, a broker, or a marketing agency, that ambiguity is deliberate.

It is fair to hold us to this list. We do not guarantee outcomes and we do not publish success rates. We do not use recovery stories as evidence. Nothing here is first-come, and there is no advantage to deciding quickly. No one at Human Paths can tell you that you are a candidate — that conclusion requires a physician who has read your records. And we ask you to involve your own medical team, rather than avoid it.

When exploring an option abroad may make sense

There are situations where looking beyond your current options is a reasonable thing to do, and it is worth naming them as plainly as the warning signs above.

Standard treatment has been exhausted, or has stopped working. When the approved options for your diagnosis have been used, exploring what else exists is not recklessness. It is what many people do, and what many oncologists will discuss with you.

You are looking for something that can run alongside your current treatment. Some approaches can be considered in parallel with standard care rather than instead of it. Whether that applies to your situation is a clinical question for your physician — but the possibility is real, and it is different from choosing one over the other.

You have time to investigate without compromising anything. If your current treatment is underway and stable, the weeks spent gathering records and getting an independent opinion cost you nothing clinically.

You want an additional medical opinion. A physician reviewing your case may conclude that a particular treatment is not appropriate for you, and that conclusion is itself useful information. Having a second qualified perspective on your situation has value regardless of what it recommends.

You are able to do this without financial or logistical harm. If exploring an option does not compromise your household, your ability to continue standard care, or your capacity to travel safely, the downside of investigating is small.

Exploring is not the same as committing. Gathering information, having your records reviewed, and speaking with a physician are reversible steps. You can stop at any of them.

When traveling for treatment may not make sense

Some situations make international treatment a poor choice regardless of the therapy:

• Your current treatment is working, and interrupting it carries risk.
• Your condition makes travel medically inadvisable — ask your physician directly.
• You would need to fund it in a way that compromises your household or your ability to continue standard care.
• You do not have someone who can travel with you and help manage logistics.
• The provider cannot explain clearly what happens if complications arise after you return home.
• You are being asked to decide in a state of acute distress, shortly after receiving bad news.

That last one deserves emphasis. A cancer diagnosis produces fear, and fear compresses decision-making. If you are in the first days or weeks after news that changed everything, the most useful thing you can do is slow down — not stop looking, but stop deciding.

What a review gives you, and who decides

If you continue, an independently licensed physician reviews your medical information and reaches a conclusion about whether this treatment is appropriate for your situation. That is what this process produces: your case organized, and an independent medical opinion on it.

That physician may conclude that you are not an appropriate candidate. If that happens, you will be told — and that answer is worth having. A qualified opinion that something is not right for you is information you did not have before, and it closes a question rather than leaving it open.

Human Paths does not make that determination. We are an administrative and technology platform: we collect and organize information, facilitate communication, and coordinate logistics. We do not provide medical advice, make diagnoses, recommend treatment, or determine eligibility. We do not sell or bill for healthcare services. Any fees are established and communicated directly by the treating physician.

What this means for you: submitting information to us is not an application that we approve. It is a step toward a physician reviewing your case and reaching an independent conclusion.

If you decide to look further

The next step is not a commitment. It is a review.

A physician needs your medical records to say anything meaningful about your situation — pathology reports, imaging, treatment history. Gathering those takes time and usually requires requesting them from the institutions that hold them. We explain that process, and we help you through it, in Preparing Your Records.

If you decide not to continue, nothing further happens. You can stop at any point, and you can ask us to delete your information.

This page provides general information and is not medical advice. It does not establish a physician-patient relationship. Decisions about your treatment should be made with your treating physician.